EUCTR2016-002211-18-DE进行中（未招募）1 期
A 12-week double-blind, randomized, multicenter study comparing the efficacy and safety of once monthly subcutaneous 140 mg AMG 334 against placebo in adult episodic migraine patients who have failed 2-4 prophylactic treatments (LIBERTY)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Documented history of migraine (with or without aura) for = 12 months prior to screening according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3)
- •- 4 to 14 days per month of migraine symptoms (based on ICHD-3 criteria) on average across the 3 months prior to screening based on retrospective reporting
- •- <15 days per month of headache symptoms (ie migraine and non-migraine)
- •- Failed 2 to 4 prior migraine prophylaxis treatments out of the following: Propranolol/metoprolol, topiramate, flunarizine, valproate/divalproex, amitriptyline, venlafaxine, lisinopril, candesartan, locally approved products (e.g. oxeterone or pizotifen)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 210
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Older than 50 years of age at migraine onset
- •- Unable to differentiate migraine from other headaches
- •- History of cluster headache or hemiplegic migraine headache
- •- Failed more than 4 prior migraine prophylaxis treatments [as specified in protocol]
- •- Use of a prophylactic migraine medication within 5 half-lives, or a device or procedure within one month prior to the start of the baseline phase or during the baseline phase
- •- Prior Botulinum toxin A treatment in the head/neck region (including cosmetic use or other licensed indications for Botox ®) within 4 months prior to start of or during the baseline phase
- •- Use of the following for any indication in the 1 month prior to the start of the baseline phase or during the baseline phase:
- •o ergotamines or triptanes =10 days/month, or
- •o simple analgesics (NSAIDs, acetaminophen, paracetamol) =15 days/month, or
- •o opioid- or butalbital-containing analgesics =4 days/month
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the effects of AMG334 compared to placebo medication in the prophylactic treatment of migraine in adult patients who have already tried other prophylactic migraine treatments unsuccessfullyMigraine PreventionMedDRA version: 19.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002211-18-ESovartis Farmacéutica S.A246
进行中（未招募）
1 期
A study to evaluate the effects of AMG334 compared to placebo medication in the prophylactic treatment of migraine in adult patients who have already tried other prophylactic migraine treatments unsuccessfullyMigraine PreventionMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002211-18-SEovartis Pharma Services AG220
进行中（未招募）
1 期
A study to evaluate the effects of AMG334 compared to placebo medication in the prophylactic treatment of migraine in adult patients who have already tried other prophylactic migraine treatments unsuccessfullyMigraine PreventionMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002211-18-NLovartis Pharma Services AG220
进行中（未招募）
1 期
A study to evaluate the effects of AMG334 compared to placebo medication in the prophylactic treatment of migraine in adult patients who have already tried other prophylactic migraine treatments unsuccessfullyEUCTR2016-002211-18-BEovartis Pharma Services AG382
进行中（未招募）
1 期
A study to evaluate the effects of AMG334 compared to placebo medication in the prophylactic treatment of migraine in adult patients who have already tried other prophylactic migraine treatments unsuccessfullyMigraine PreventionMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002211-18-ATovartis Pharma Services AG220